| Hans-Günter Meyer-Thompson | Legal
USA. A mega-case puts opioids on trial
(...) At a minimum, pretrial discovery might force drug companies to do something they have heretofore fiercely resisted: produce their internal records, including any that show discrepancies between what they told doctors, regulators and the public about opioids, and what they knew or suspected privately. (Washington Post, 05.10.2016)